Financials data is unavailable for this security.
View more
Year on year Linical Co Ltd 's net income fell -66.32% from 1.00bn to 338.27m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 66.75% to 69.30%.
Gross margin | 29.26% |
---|---|
Net profit margin | 2.08% |
Operating margin | 4.20% |
Return on assets | 1.38% |
---|---|
Return on equity | 3.18% |
Return on investment | 2.37% |
More ▼
Cash flow in JPYView more
In 2024, Linical Co Ltd increased its cash reserves by 6.01%, or 423.09m. The company earned 1.07bn from its operations for a Cash Flow Margin of 8.66%. In addition the company used 28.50m on investing activities and also paid 960.93m in financing cash flows.
Cash flow per share | 34.86 |
---|---|
Price/Cash flow per share | 12.51 |
Book value per share | 362.32 |
---|---|
Tangible book value per share | 194.71 |
More ▼
Balance sheet in JPYView more
Current ratio | 1.55 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.3365 |
---|---|
Total debt/total capital | 0.2518 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share increased 7.14% while earnings per share excluding extraordinary items fell by -66.32%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 2.14% |
---|---|
Div growth rate (5 year) | 4.56% |
Payout ratio (TTM) | 134.21% |
EPS growth(5 years) | -9.80 |
---|---|
EPS (TTM) vs TTM 1 year ago | -72.88 |
More ▼